| Identification | Back Directory | [Name]
4-((1-((2,4-dichlorophenyl)sulfonyl)-3-hydroxyazetidin-3-yl)methoxy)-2-fluorobenzonitrile | [CAS]
1669444-50-1 | [Synonyms]
4-((1-((2,4-dichlorophenyl)sulfonyl)-3-hydroxyazetidin-3-yl)methoxy)-2-fluorobenzonitrile
Benzonitrile, 4-[[1-[(2,4-dichlorophenyl)sulfonyl]-3-hydroxy-3-azetidinyl]methoxy]-2-fluoro- | [Molecular Formula]
C17H13Cl2FN2O4S | [MDL Number]
MFCD30470490 | [MOL File]
1669444-50-1.mol | [Molecular Weight]
431.27 |
| Chemical Properties | Back Directory | [Boiling point ]
604.6±65.0 °C(Predicted) | [density ]
1?+-.0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
12.06±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
PF-05214030 is a novel potent TRPV4 antagonist (hTRPV4 IC50 4nM; rTRPV4 IC50 27nM). | [Uses]
PF-05214030 is a TRPV4 antagonist (IC50: 4 and 27nM for hTRPV4 and rTRPV4 respectively). PF-05214030 reverses the reduction in bladder capacity caused by intravesical infusion of a TRPV4 agonist[1][2]. | [References]
[1] Jiang Y, et al. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022 Mar 24;15(1):34. DOI:10.1186/s13045-022-01252-0
[2] Sarah Skerratt, et al. The Discovery and Optimisation of a Highly Selective Series of TRPV4 Antagonists. |
|
| Company Name: |
Struchem Co., Ltd.
|
| Tel: |
0512-63009836 18994340901 |
| Website: |
www.beidapharma.com |
|